1. Results of the Inclusion of New Medications in the Obligatory Health System Plan in Colombia, 2012–2013 
Jorge Enrique Machado-Alba, PhD, Daniel Torres, MSc, Alfredo Portilla, MSc, Andrés Felipe Ruiz, MSc 
Value in Health Regional Issues 
Volume 8, Pages (December 2015)
DOI: /j.vhri
Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1
Consumption trends per dosage per 1000 inhabitants per day, comparing the new medication included in the Agreement 029/2012 versus a similar mandatory health plan (Colombia 2011–2013).
Value in Health Regional Issues 2015 8, 28-35DOI: ( /j.vhri )
Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
Consumption trend per dosage per 1000 inhabitants per day, comparing atorvastatin versus lovastatin (A), esomeprazole versus omeprazole (B), sertraline versus fluoxetine (C), and insulin glargine versus insulin isophane zinc (NPH). DHD, Dose inhabitant per day; NPH, Neutral Protamine Hagedorn. (Colombia 2011–2013).
Value in Health Regional Issues 2015 8, 28-35DOI: ( /j.vhri )
Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

4. Fig. 3
Cost trends per 1000 people per day compared with new medications including the Agreement 029/2012 versus the mandatory health plan, Colombia (2011–2013).
Value in Health Regional Issues 2015 8, 28-35DOI: ( /j.vhri )
Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions